Structural basis for the activity of the type VII CRISPR–Cas system
Jie Yang(Tianjin Medical University), Heng Zhang(South China University of Technology), Tongyao Wang(Editas Medicine (United States)), Xuzichao Li(Ministry of Education), Hang Yin(Cornell University), Xiaoshen Wang(Tianjin Medical University), Zhikun Liu(Tianjin Medical University), Haiyan Zhao(Hubei University of Medicine), Jingjing Tang(Chinese Academy of Sciences), Qiuqiu He(Tianjin Medical University), Fumeng Liao(Tianjin Medical University), Shuqin Zhang(Tianjin Medical University), Lingling Zhang(Tianjin Medical University), Feiyang Yu(Wuhan University), Yi Zhang(Tianjin Medical University), Zengqin Deng(Chinese Academy of Sciences)
Cited by 31
Related Papers
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
|Cell Host & Microbe|2021|851
Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10
|Nature Medicine|2019|708
Evidence that opioids may have toll-like receptor 4 and MD-2 effects
|Brain Behavior and Immunity|2009|574
Morphine activates neuroinflammation in a manner parallel to endotoxin
|Proceedings of the National Academy of Sciences|2012|512